Peter Greenleaf, Aurinia CEO
May 11, 2023 07:19 AM EDTUpdated 11:27 AM
People

Au­rinia’s board gets push­back from an­oth­er share­hold­er as Iljin fol­lows MKT Cap­i­tal’s lead

Kyle LaHucik

Senior Reporter

It’s the not-so-lucky sev­en for Au­rinia Phar­ma­ceu­ti­cals.

Ko­re­an in­vestor Iljin SNT is with­hold­ing sup­port for sev­en of the Cana­di­an biotech’s eight …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Biotech seed rounds sink to low­est lev­el in years as in­dus­try slump drags on

US drugs re­ly heav­i­ly on in­gre­di­ents made over­seas, new re­port shows

Phar­ma's wins and loss­es in Trump's sprawl­ing ex­ec­u­tive or­der on drug prices

Sarep­ta los­es CMO to RNA edit­ing up­start; An­oth­er wave of per­son­nel moves at Dyne

Sanofi to pay $125M up­front for two im­munol­o­gy drugs from lit­tle-known biotech

sponsored

New York-based part­ner­ship sets the stan­dard for ex­pand­ing clin­i­cal tri­al ac­cess for un­der­served and di­verse ...

A service from the Financial Times